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Abstract
Background: To determine reference intervals for serum levels of human epididymis protein 4 (HE4) in Chinese
women.
Methods: In this multicenter (n = 9) study, 618 healthy women, 767 patients with non-malignant diseases, and 951
patients with malignant tumors were enrolled. Serum levels of HE4 were measured in all patients using
electrochemiluminescence immunoassays. The influence of age, menopause, malignancy status and other
characteristics on the levels of HE4 was evaluated using univariate and multivariate analyses. Confidence intervals
(2.5–97.5 %) were determined in different populations.
Results: There were significant differences in HE4 levels among groups with different ages, menopause or
malignancy status. Higher levels of HE4 were detected in elder compared to younger, post- compare to pre-
menopause and malignant compared to benign subjects. Multivariate analysis showed that menopause and
malignancy status, as well as smoking and pelvic masses were independent factors involved in serum HE4 levels. In
pre-menopause stage, the reference ranges of HE4 level were 29.30–68.79, 28.12–1284.83 and 34.75–981.91 pmol/L
in healthy, benign and malignant populations, respectively. In post-menopause stage, the reference ranges are
35.96–114.43, 39.11–2208.70 and 39.40–1678.13 pmol/L for those populations.
Conclusions: The present study has established the reference intervals of HE4 levels in pre- and post-menopause
populations with different malignancy status.
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Background
Ovarian cancer is one of the most common gynecologic
cancers all over the world. The estimated annual inci-
dence is 225,500 cases worldwide, and 140,200 patients
die every year from the disease [1]. In China, the inci-
dence of ovarian cancer has also increased in recent
years, and it is now ranking the eighth most common
cancer [2]. Despite the improvement of surgical tech-
niques and development of a number of anti-tumor
drugs and new therapies, the 5-year survival rate of late-
stage ovarian cancer is only 30 % [3]. Therefore, early
diagnosis of ovarian cancer is critical for prognosis and
long-term survival. Unfortunately, due to the lack of spe-
cific symptoms at early stages, most patients are diag-
nosed only in late stages [4, 5].
The human epididymis protein 4 (HE4) (also called
WFDC2) was originally identified as a small secreted
protein that plays a role in sperm maturation in males
[6], and it was found to be expressed in some ovarian
cancers [7, 8]. Serum levels of HE4 have been shown to
be useful for the diagnosis of ovarian cancer [9–11]. Not
only may it be used to predict malignant status of pelvic
mass, the HE4 level is also correlated with malignancy
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level and complexity of the disease [12]. In addition, it
was shown to be correlated to surgery outcomes [13].
However, despite the existence of many methods for
HE4 measurements, there is a lack of standardization
and results cannot be compared between populations
and studies. Previous studies have shown that age, fertility
status, menopause, smoking, renal function, ethnicity, and
detection method may affect serum HE4 levels [14–18].
Therefore, reference intervals of serum HE4 levels need to
be established in different populations stratified according
to these factors. In addition, only limited data are available
on HE4 levels in Han Chinese individuals living in China
[17]. Therefore, there are large variations in HE4 reference
ranges, causing uncertainty in clinical application.
Nevertheless, recent studies have described HE4 as a
specific and useful biomarker for early diagnosis of epi-
thelial ovarian cancer (EOC), which account for 90 % of
all ovarian cancers [19]. In addition, incorporation of
serum levels of HE4 and CA125 in the Risk of Ovarian
Malignancy Algorithm (ROMA) [18] for clinical evalu-
ation have resulted in improved EOC diagnosis specifi-
city and sensitivity, and have helped distinguish
malignant from benign pelvic masses [20, 21]. Other
studies have equally demonstrated the importance of
HE4 in predicting ovarian cancer recurrence [22, 23].
Therefore, the present multicenter study was under-
taken to determine the factors influencing HE4 levels




This multi-center (n = 9) study prospectively included
healthy women and female patients (n = 2351) from
October 2012 to February 2013. All participating sites
received the approval of their ethics committee. The
need for informed consent was waived by the commit-
tees since all specimens used in the present study were
leftover samples.
The inclusion criteria for all individuals were: 1) Clinical
records including age, menopause status, race, sex, smok-
ing history, diagnosis of benign disease patients and
pathological results were available; and 2) normal appear-
ance of blood samples, with at least 0.5 ml being available.
The exclusion criteria were: 1) patients <18 years old; 2)
incomplete clinical data; 3) insufficient blood sample vol-
umes (<0.5 ml); 4) blood stored or shipped at >0 °C; 5)
samples submitted to >3 freeze/thaw cycles; or 6) blood
sample with icteric, lipemic, hemolytic appearance or par-
ticles. Clinical diagnosis of the subjects included appar-
ently healthy (618 specimens), non-malignant diseases
(767 specimens) and malignant tumors (951 specimens in-
cluding 287 EOC).
EOC diagnosis was confirmed by pathological ana-
lyses, and the EOC surgical staging was recorded.
HE4, CA125, E2, and Prog
All blood samples were taken at the time of primary
diagnosis. At the time of blood sampling, no patient has
been experienced any chemo- or radio- therapy. Blood
specimens were centrifuged to obtain serum (at least
0.5 ml), and samples were frozen at −80 °C until ana-
lysis. HE4 and CA125 serum levels were determined in
all samples using a Roche Elecsys Cobas 601 platform
(Roche Diagnostics, USA) using specific assays and kits
from for the detection of HE4 (Roche Diagnostics, Basel,
Switzerland) according to the manufacturer’s instruc-
tions. The assay method used was electrochemilumines-
cence immunoassay (ECLIA) and the measurement range
was 15.0–1500 pmol/L for HE4 All laboratories involved
in this study passed the External Quality Assessment
(EQA)/ISO 15189, as required by Chinese authorities. The
same batch number reagents and controls were used in la-
boratories in all sites. All these laboratories passed the ex-
ternal quality assessment before the study.
Statistical analysis
Statistical analyses were performed using SPSS 18.0
(IBM, Armonk, NY, USA). Box-Cox regression was used
for data transformation to obtain a normal distribution.
Quantitative values are reported as N, median (range).
Qualitative variables were described as numbers. One
way ANOVA and Bonferroni post hoc test were used for
comparisons. Reference intervals were determined by
selecting the 2.5 and 97.5 percentiles. Multivariate linear
regression analysis was used to evaluate correlations be-
tween different factors with HE4 levels. Differences were
considered statistically significant at P < 0.05.
Results
Study population
A total of 2351 subjects were enrolled in the study in-
cluding 618 healthy volunteers, 287 patients with epithe-
lial ovarian cancer according to Federation International
of Gynecology and Obstetrics (FIGO) staging and 1446
patients with various benign diseases and other cancers.
The medium age was 49 (range 18–95) years. There
were 1213 subjects in pre-menopause, 1137 post-
menopause and 1 with unknown status (Table 1).
In the analysis of HE4 levels, 15 samples with com-
bined benign and malignant diseases, 1 sample with un-
known menopause status, and 4 samples with
unspecified out-of-upper-limit HE4 levels were excluded,
resulting in 2331 samples included in the final analysis.
The numbers of samples included and excluded in dif-
ferent sitess were listed in Additional file 1: Table S1. To
gain a rough estimate of HE4 levels in the general
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population, the reference ranges (95 % CI) of HE4 levels
in the healthy population in this study were evaluated in
different age groups as well as in pre- and post- meno-
pause subjects (Table 2).
Factors that influence HE4 levels
It has been previously noticed that HE4 level in individ-
uals could be affected by various factors including age,
menopause and diseases [14–18]. To determine which
factors could interfere with HE4 level, study subjects
were grouped based on age, menopause, and disease. As
shown in Table 3, significant differences in HE4 levels
were detected in patients grouped in each category.
Aging, menopause, malignant diseases and increased sta-
ging of ovarian cancer seemed all result in increased
levels of HE4. These results indicate that multiple inter-
fering factors have to be considered to establish a refer-
ence interval of HE4 level.
To confirm the interfering factors of HE4 levels in in-
dividual, multivariate linear regression analyses were
used to identify the correlations between different char-
acteristics and HE4 levels. As shown in Table 4, when
only age, menopause and malignancy status were consid-
ered, menopause and malignancy status, but not age,
were independently associated with HE4 levels. When
pregnancy status, smoking, and existence pelvic masses
were added into the analysis, menopause and malig-
nancy status were still independently associated with
HE4 levels. Smoking and pelvic masses were also signifi-
cantly associated with HE4 levels. Age seemed not to be
an independently associated factor.
HE4 reference range in different populations
Results indicated that the presence of an ovarian tumor
and menopause status, but not age, had to be considered
when determining whether HE4 levels are abnormal.
The post-menopausal population generally had higher
HE4 levels compared with pre-menopausal individuals.
The presence of a malignant tumor, mostly ovarian can-
cer, could further increase HE4 levels. The detailed refer-
ence intervals of HE4 levels in healthy, individuals with
benign tumors or malignant tumors, for pre- and post-
menopause populations, are listed in Table 5. In pre-
menopause stage, the reference ranges of HE4 level were
Table 2 HE4 reference range in healthy populations according to age or menopause status
Number Value (mean ± SD) Reference range (2.5–97.5 %)
Ages*
<40 201 45.85 ± 10.72 29.25–68.50
40–49 102 47.80 ± 9.73 32.11–68.96
50–59 104 54,11 ± 14.30 33.04–88.67
60–69 108 59.91 ± 14.33 34.72–92.35
≥70 103 77.57 ± 23.20 45.18–132.00
Pre-menopause 308 46.61 ± 10.70 29.25–68.96
Post-menopause 310 63.94 ± 20.21 34.72–114.90
Overall 618 55.30 ± 18.35 31.82–105.10
*A statistical significant difference in HE4 was found between each age group (p < 0.0001) except between <40 and 40–49







Benign disease 767 (32.6)
Benign gynecologic tumor 348
Other gynecological disease 70
Pregnant 108
Congestive heart failure 43
Renal failure 74
Other benign diseases 124
Malignant disease 951 (40.5)











Mixed benign and malignant disease 15 (0.6)
Total 2351
Age median (range) 49 (18–95)
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29.30–68.79, 28.12–1284.83 and 34.75–981.91 pmol/L in
healthy, benign and malignant populations, respectively.
In post-menopause stage, the reference ranges are
35.96–114.43, 39.11–2208.70 and 39.40–1678.13 pmol/L
for those populations. In addition, HE4 and CA125 dis-
tribution in patients of different EOC stages also showed
significant differences (Fig. 1).
Discussion
As mentioned previously, ovarian cancer at early stages
can be effectively treated with surgery with significantly
higher 5-year survival rate [3]. However, most ovarian
cancers are diagnosed in their late stages and this is also
one of the reasons why the acceptance of laparoscopic
surgeries for ovarian cancer is much slower than that for
other malignant female reproductive cancers [24].
Ghezzi et al. [25] and Bae et al. [26] described that min-
imally invasive surgeries, such as laparoscopic staging or
restaging of early stage ovarian cancer are as safe and ef-
fective as open abdominal surgery. A systemic review
also demonstrated that patients undergoing laparoscopic
surgeries had lower blood loss, shorter hospital stay
period and shorter time interval between surgery and
chemotherapy compared with open abdominal surgery
[27]. Therefore, diagnosis of the disease in early stages
plays a critical role in the timely treatment and will bring
more benefits for the patients. As a correlated biomarker
with ovarian disease, HE4 may facilitate to optimize the
early diagnosis of ovarian cancer. To the best of our
knowledge, this is the first prospective multicenter study
examining age-related reference ranges of serum HE4
levels in a Chinese population. The 2.5–97.5 % cut-offs
were determined in different patient subpopulation.
There were significant differences in HE4 levels among
groups with different ages, menopause or malignancy
status. Multivariate analysis showed that menopause and
malignancy status, as well as smoking and pelvic masses
were independent factors involved in serum HE4 levels.
Different studies indicated different effects of patients’
characteristics on HE4 levels. Ferraro et al. [14] have
shown that the menopausal status was associated with
HE4 levels, as well as smoking and renal function.
Speeckaert et al. [11] have shown that menopause was
associated with HE4 levels. A meta-analysis supported
the previous point of view and also showed that the de-
tection method was associated with HE4 variations as
well [16]. A study has shown that longitudinal measure-
ment of HE4 levels might be better than cross-sectional
ones [28]. but the applicability of this approach in the
clinical setting might be more difficult. A study in mul-
tiple Asian ethnicities revealed that age was associated
with HE4 levels, as well as ethnicity (Malays vs. Indians
and Chinese) [17]. Moore et al. [15] have shown that
age, menopausal status and pregnancy were associated
with HE4 levels. Taken together, these studies suggest that
there are variations in the factors influencing HE4 levels
among different populations. These differences might be










Pelvic masses 68.517 <0.001
Malignancy status 53.140 <0.001
Model 1: age, menopause and malignancy status were included. Model 2: age,
menopause, malignancy status, pregnancy, smoking, and pelvic masses were
included. The associations with HE4 levels were analyzed using multivariate
linear analysis using the enter regression method
Table 5 Reference ranges of HE4 in different populations







Table 3 Influences of age, menopause or malignancy on HE
levels
Parameter Number HE4 Value P
Median (range)
Age <0.001
<40 628 47.275 (15–2982)
40–49 544 51.01 (24.07–4322)
50–59 520 59.47 (26.08–5234)
60–69 371 66.63 (23.3–3844)
≥70 268 84.33 (24.22–2276)
Menopause <0.001
Pre-menopause 1206 48.81 (15–4322)
Post-menopause 1125 68.46 (23.3–5234)
Malignancy status <0.001
Healthy 618 51.09 (23.3–166)
Benign 765 51.92 (15–5234)
Malignant 948 67.935 (26.08–4603)
Overall 2331 56.51 (15–5234)
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population-specific, or may be the result of the small sam-
ple size observed in some studies. Further studies focusing
on specific populations should determine the factors influ-
encing HE4 levels before generalizing to other popula-
tions. In the present study, menopause, malignancy status,
smoking, and pelvic masses were independent factors as-
sociated with serum HE4 levels.
A recent meta-analysis revealed that the capacity of
HE4 in identifying malignant from benign lesions was
high [16]. Beside the cancer itself, the histological type
and cancer stage are associated with HE4 levels as well
[11]. HE4 levels in EOC patients in this study were sig-
nificantly higher than the subjects with benign diseases.
Apparently the diagnostic value of HE4 level would be
only significant at the early disease stages. Our data
showed that the HE4 levels in stage I/II patients were
significantly higher than that in subjects with benign
ovarian disease, further indicating the value of HE4 as
an early diagnosis marker. A study has shown that HE4
levels were better than CA125 levels for detecting
ovarian cancer [29], which is supported by a meta-
analysis [30]. A recent study revealed that the combin-
ation of HE4 levels with pelvis ultrasound achieved the
best sensitivity for detecting ovarian cancers among dif-
ferent algorithms tested [31]. Further study is necessary
to determine if the combination of HE4 measurements
with other diagnostic modalities could promote the de-
tection of ovarian cancer. Algorithms could be designed
for the rapid screening of asymptomatic women.
The present study suggested that while using HE4 level
as a potential indicator of ovarian cancer, other factors for
each individual such as menopause, but not age, must be
considered. Reference ranges need to be established after
considering those interfering factors. The strength of the
present study is that it had a relatively large sample size
and samples were from multiple centers. However, there
was also a limitation due to the variety of interfering fac-
tors, and the unavailability of some factors in a retrospect-
ive setting. Further study with larger sample size is needed
to establish reliable reference ranges.
Fig. 1 HE4 and CA125 distribution in EOC patients according to cancer stage. a and c, pre-menopause; b and d, post-menopause
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Conclusion
In conclusion, the present study has established the refer-
ence intervals of HE4 levels in pre- and post- menopause
populations with different malignancy status.
Additional file
Additional file 1: Table S1. The detailed numbers of subjects from
different centers. (DOCX 17.3 kb)
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